Аминовен

Quick links

Choose a section

Quick links to important sections

Advertisements

Аминовен

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Аминовен

Quick Facts

Property Description
Active ingredient L-Amino acids (essential, non-essential, and conditionally essential)
Form Aqueous Solution for Infusion
Pharmacological class Solutions for Parenteral Nutrition (ATC B05BA)
General purpose Nutritional support and maintenance of protein balance
Origin Synthetic (chemically defined blend)

What Type of Medicine is Аминовен?

Аминовен (Aminoven) is a specialized pharmaceutical preparation that is categorized as an aqueous solution for infusion, primarily used to provide essential nutritional support through the intravenous route. It is a prescription-only, combination product that belongs to the high-level Nutritional supplements pharmacological class, specifically B05BA Solutions for parenteral nutrition. The core function of this form is to deliver nutrients that completely bypass the digestive system.

Composition: The Balanced Mix of Amino Acids

The defining active ingredients in Аминовен are a comprehensive and precise blend of purified, synthetic L-amino acids, encompassing all the necessary essential amino acids and non-essential amino acids required as protein building blocks. The formulation is specifically designed to deliver these nutrients in a balanced, readily available profile. Clinical guidance confirms that such standard amino acid preparations are used to ensure the nitrogen requirements are met in patients needing intravenous feeding.

What is the General Purpose of Аминовен?

The general purpose of administering Аминовен is to supply the body with the materials necessary for robust protein synthesis and to counteract the severe tissue breakdown common during critical illness or surgical recovery. The preparation’s balanced profile provides immediate access to amino acids for tissue repair and to preserve muscle maintenance. This direct nutritional intervention is effective in helping the patient achieve and maintain a positive nitrogen balance, which is the measurable goal of intravenous nutritional therapy. This makes it a primary choice in providing specialized feeding when the gastrointestinal function is impaired.

Advertisements

What side effects are possible with Аминовен?

Possible Side Effects and Safety Information

The official safety profile for Aminoven, a solution for parenteral nutrition, primarily structures risks around administration technique and patient susceptibility, rather than inherent drug toxicity. Specific frequency classifications (e.g., Common, Rare) are typically not assigned to individual adverse reactions in regulatory labeling; instead, effects are often documented as consequences of improper use.

Adverse events are largely administration-dependent and reversible, documented to occur when the maximum recommended infusion rate is exceeded. These transient systemic effects may include nausea, vomiting, shivering (chill), and fever. Local adverse reactions at the infusion site, such as thrombophlebitis and irritation of the vein wall, are noted, particularly when the infusion is administered via a peripheral vein.

The regulatory documents classify potential serious outcomes, focusing on metabolic consequences and contraindications. Serious adverse events include hypersensitivity/allergic reactions and severe metabolic complications like hyperammonemia and profound metabolic acidosis, which can result from exceeding dosage guidelines or from underlying patient vulnerability.

Safety Constraints and Special Populations

Aminoven is contraindicated in specific conditions involving severe organ compromise or metabolic error, which define the strict limits of its use. This includes patients with severe kidney failure (without dialysis), severe liver failure (hepatic coma), severe metabolic acidosis, and known Inborn Errors of Amino Acid Metabolism.

Population-specific safety considerations include contraindications for certain formulations in newborns and children less than two years of age. Furthermore, an increased risk of aluminum toxicity is a documented safety concern for all parenteral nutrition solutions, particularly in patients with impaired renal function.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define an overdose of Aminoven as primarily associated with an exceeded infusion rate. This rapid administration of the amino acid solution can lead to specific clinical signs and severe physiological consequences.

Category Officially Documented Statement
Manifestations Symptoms include nausea, vomiting, and shivering. Signs include increased renal amino acid losses.
Severe Outcomes Consequences of fluid overload, such as pulmonary oedema, and severe electrolyte disturbances are possible.
Immediate Action The infusion must be stopped immediately upon the appearance of any overdose symptoms.

The most common signs of overdose are associated with fluid and amino acid intolerance, not toxicity from a fixed dose. If symptoms of overdose occur, emergency medical care is required to manage potential complications like pulmonary oedema. Management involves supportive general measures, with particular attention directed toward the respiratory and cardiovascular systems. The regulatory labeling confirms that no specific antidote is known for this condition. The potential to continue with a reduced dosage may be considered only after stabilization. For the infant formulation, specific procedures for managing hyperkalaemia in overdose are also documented.

Advertisements

Therapeutic Uses of Аминовен

What Aminoven Treats: Main Uses and Benefits

Aminoven is generally used when supportive symptom management is appropriate in contexts where nutritional support is needed, such as when oral or enteral nutrition is not possible, insufficient, or contraindicated. Its use is consistent with guidance for similar parenteral nutrition components. The medicine is applied across domains where additional symptomatic support is needed to help maintain the body's functional stability.

Supporting Symptom Management During Recovery

This medicine is considered relevant in clinical settings that involve acute or unstable symptom patterns, such as during phases of recovery from major surgery, trauma, or severe illness. It may assist with supportive symptom management during difficult episodes and may help address symptom clusters that create noticeable physiological strain, which contributes to improved comfort during periods of heightened symptoms. The medicine is relevant for addressing conditions that present with systemic or localized discomfort, assisting during episodes of increased physiological stress, and providing support when symptoms interfere with routine activities.

“It assists with maintaining functional stability, thereby helping patients cope more steadily with symptom fluctuations.”

Quick Fact: Supports in managing symptomatic discomfort

Assistance During Periods of Increased Stress

Applied during phases when symptoms become more noticeable, this medicine provides supportive relief when symptoms intensify and temporary assistance in symptom stabilization is important. It is useful in scenarios where a condition produces significant symptomatic burden and requires short-term symptomatic assistance.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Aminoven?

The eligibility for Aminoven use is strictly defined by regulatory documents, which list specific absolute prohibitions (contraindications) and age-based limitations.

Category Official Regulatory Status
Populations for whom use is allowed Adults are eligible for use across all concentrations. Children and adolescents (2–18 years) are eligible for lower concentrations like 8% and 16% [Source 1.1].
Populations for whom use is contraindicated Individuals with disturbances of amino acid metabolism, metabolic acidosis, advanced liver insufficiency, or renal insufficiency without access to haemodialysis or haemofiltration treatment [Source 1.1, 2.6]. Use is also prohibited in patients experiencing shock, hypoxia, fluid overload, or decompensated heart failure [Source 2.4, 2.6].
Age-related eligibility rules Children less than 2 years of age are contraindicated for most standard formulations (5%, 8%, 10%, 16%), and a separate paediatric preparation should be used. Aminoven 25% is contraindicated in all children and adolescents [Source 2.4, 2.6].
Pregnancy and lactation eligibility Safety has not been established. Use is conditional upon a careful risk/benefit relationship consideration [Source 3.2].

Official regulatory labels also require caution for patients with cardiac insufficiency when large volumes are infused, and for those with hypokalemia or hyponatremia, who require simultaneous electrolyte correction [Source 2.4]. These official eligibility domains establish who can and cannot safely receive the medicine according to governmental prescribing information.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Аминовен (Amino acid solution) is structured primarily around admixture compatibility rules and component-related cautions, as systemic drug-drug interactions are not known to be documented.

Interaction Scope

Category Official Regulatory Statement
Systemic Pharmacological Interactions None are known to date with other medicinal products.
Admixture Restriction The solution must not be mixed with other medicines due to the risk of physical and chemical incompatibility and microbiological contamination.
Admixture Conditions If other nutritional components (e.g., electrolytes, trace elements) are necessary, confirmed compatibility and the use of aseptic techniques are mandatory prior to blending and administration.
Population-Specific Caution The product contains aluminum, which is officially associated with a risk of toxicity, specifically accumulation with prolonged parenteral administration in patients with impaired renal function.

Connection to the overall interaction profile

The regulatory documents establish the product's interaction structure based entirely on procedural constraints related to its use as an intravenous solution, explicitly prohibiting co-administration with other medicines in the same container due to incompatibility risks. An essential restriction is also noted regarding the risk of aluminum accumulation in patients with impaired kidney function receiving prolonged parenteral feeding.

Advertisements

Mechanism of Action

Аминовен is a solution of essential and non-essential amino acids which provides the substrates for protein synthesis, ensuring the availability of nitrogen. The delivery of these amino acids influences the dynamic of nitrogen pools, resulting in a shift toward nitrogen retention. Branched-chain amino acids, such as leucine, act as signaling molecules and substrates for the mTOR pathway, leading to the stimulation of muscle protein synthesis. Specific amino acids like glutamine act as metabolic fuels for rapidly dividing cells, such as enterocytes and lymphocytes. Glutamine also functions to modulate the systemic stress response, potentially influencing the rate of whole-body protein catabolism. The provision of an exogenous amino acid load mitigates the reliance on endogenous protein stores, thereby affecting the rate of peripheral tissue proteolysis.

Advertisements

Dosage and Administration Information

Administration of Aminoven

Aminoven is a solution intended for parenteral nutrition, meaning it is delivered directly into the venous system. Because it is designed to provide the body with essential amino acids when oral or enteral feeding is impossible, insufficient, or contraindicated, its administration follows specific clinical protocols regarding the site and method of delivery.

Method of Delivery

The solution is administered via a continuous intravenous infusion. For most formulations of this amino acid solution, delivery is managed through a central vein. This is necessary because the osmolarity of the solution requires a high-flow vessel to ensure proper dilution and to protect the integrity of the smaller peripheral veins.

In specific clinical circumstances where a more dilute concentration is used, peripheral venous administration may be considered, though this is determined based on the total osmolarity of the final nutrient mixture.

Duration of Use

Aminoven is used as long as parenteral nutrition is clinically required. The duration of therapy depends entirely on the patient's nutritional status, their ability to transition back to regular food intake, and the underlying clinical condition. The infusion is typically maintained at a constant rate to ensure the body can efficiently metabolize the provided amino acids.

Integration into Nutrition Programs

Aminoven is rarely administered in isolation. It is generally one component of a comprehensive parenteral nutrition program that includes:

  • Energy sources: Glucose and lipid emulsions.
  • Micronutrients: Electrolytes, vitamins, and trace elements.
  • Fluid management: Total volume adjustments based on the patient's hydration needs.

The compatibility of other nutrients when mixed with Aminoven must be confirmed prior to administration to ensure the stability of the solution.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Аминовен

Evidence for Use in Parenteral Nutritional Support

This section summarizes the structure of the clinical trials, meta-analyses, and systematic reviews that established the role of amino acid solutions as a required component of nutritional support when oral or enteral feeding is not possible. The content will detail the study designs and the primary metabolic and clinical outcomes examined by researchers (e.g., nitrogen balance and length of stay).

The research for amino acid solutions like Аминовен, which are standard components of Parenteral Nutrition (PN), was evaluated in clinical research contexts involving patients experiencing acute physiological strain, such as those recovering from major surgery or suffering from severe trauma or illness. Studies explored how the infusion of this solution, as part of a total PN regimen, relates to metabolic outcomes and systemic balance. The primary focus of many studies was monitoring physiological strain by tracking nitrogen balance, a key marker for protein status. Findings describe the relationship observed in the studies between the administered amino acids and changes in nitrogen balance within the observed populations. This research contributes to the general principle of supplying protein building blocks when the digestive system cannot be used.

Research on Follow-up Duration and Long-Term Outcomes

Studies that informed the clinical application of standard amino acid solutions were frequently conducted during periods of increased symptom activity. Consequently, follow-up durations were limited, often focusing on the acute phase of treatment, such as administration over defined time intervals of up to seven days in post-operative patients. These short-term studies explored the immediate metabolic changes measured during the study period. There is limited information for long-term outcomes, and the effects of using this specific standard amino acid blend beyond the initial acute hospital stay are not fully established.

Evidence Gaps and Areas of Uncertainty

One key limitation noted in the research landscape is that comparative evidence is lacking between different standard L-amino acid formulations. While the principle of amino acid infusion is a widely accepted part of clinical practice informed by data, there is a shortage of adequately powered, randomized trials specifically designed to compare the precise composition of one standard commercial product, such as Аминовен, against another standard product based on hard clinical endpoints. Furthermore, evidence quality varies across studies, and certainty remains low regarding the potential clinical implications of a specific standard amino acid profile for all subgroups. The research does not determine whether an individual will respond similarly to the group patterns reported.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Аминовен (FAQ)

Q: What are the different strengths or concentrations of Аминовен?

A: According to official regulatory documents, this solution is manufactured and supplied in various concentrations. Common formulations available to healthcare providers include 5%, 10%, 15%, and 25% strengths, with the specific concentration determined by the patient's medical need and the route of administration.

Q: Is it normal to feel a bit flushed during the Аминовен infusion?

A: Official information documents on these types of solutions list transient effects that may occur, especially if the maximum recommended infusion rate is exceeded. While 'flushing' is not always specifically named, related effects that have been reported include chills, fever, nausea, and vomiting.

Q: Are there any long-term effects of using Аминовен for extended periods?

A: Official labeling notes that clinical trial data on the duration of therapy is often limited to the acute phase of treatment. A key long-term safety concern that is documented with prolonged parenteral administration is the risk of aluminum accumulation, particularly in patients with impaired kidney function.

Q: Does the use of Аминовен affect kidney or liver function tests?

A: Official labeling states that frequent monitoring of laboratory values, including liver enzyme tests (like transaminases) and tests for urea-nitrogen, is generally required by healthcare providers to assess the patient's metabolic status during treatment.

Q: Can patients with diabetes safely receive Аминовен?

A: Regulatory information indicates that this solution should be used with caution in patients with diabetes. Because this solution is often administered as part of a nutritional regimen that includes glucose (sugar), healthcare providers typically conduct careful blood sugar monitoring.

Q: Does taking certain vitamins affect the efficacy of Аминовен?

A: Official product information focuses on administration compatibility. If other nutritional components, such as vitamins, are added to the solution, confirmed compatibility and strict sterile techniques are mandatory to prevent physical or chemical changes and potential contamination.

Q: Can Аминовен be used in pregnant or breastfeeding women?

A: Due to the lack of dedicated studies, the safety of the solution has not been established for use during pregnancy or breastfeeding. Official labeling states that use is conditional upon a careful consideration of the potential risks versus the expected clinical benefit.

Q: What are the signs of fluid overload while on Аминовен?

A: Fluid overload is listed as a condition where the solution is contraindicated. Overdose of the solution can cause fluid overload and electrolyte imbalances, which are serious safety concerns. The potential for these effects requires close monitoring by the healthcare team.

Q: How is the effectiveness of Аминовен treatment usually monitored?

A: The effectiveness of this type of nutritional therapy is monitored through frequent evaluation of blood and urine tests. These tests include checks on urea-nitrogen, ammonia, electrolytes, and liver function to ensure the patient is responding appropriately to the nutritional support.

Q: What are the most common things people feel while receiving Аминовен?

A: Adverse effects that may occur if the infusion rate is too fast include transient symptoms like nausea, vomiting, and shivering. Local reactions at the infusion site like vein irritation or inflammation (thrombophlebitis) are also documented, especially with peripheral vein administration.

Q: Is Аминовен considered a type of nutritional support?

A: Yes, it is officially classified as a nitrogen source for partial or total parenteral nutrition therapy. Its purpose is to provide nutritional support when feeding through the mouth or digestive tract is impossible, insufficient, or medically contraindicated.

Q: Is Аминовен the same as just receiving saline solution?

A: No. Saline is a simple solution of sodium chloride and water. This solution is a complex pharmaceutical blend of L-amino acids (essential and non-essential) used to provide the body with protein building blocks.

Q: Does Аминовен contain all the essential amino acids?

A: Yes, official composition information confirms that the product is composed of a comprehensive blend of L-amino acids. This blend is specifically formulated to include all the necessary essential amino acids required as protein building blocks for the body.

Q: Does Аминовен contain any sugars or carbohydrates?

A: Standard formulations of this specific product contain L-amino acids and do not typically include sugars or carbohydrates. However, for complete nutritional support, it must be administered alongside non-protein energy sources such as glucose (dextrose) and lipids.

Q: What research supports the use of Аминовен in critically ill patients?

A: Clinical data supporting the use of standard amino acid solutions for parenteral nutrition are based on studies in patients experiencing acute physiological strain, such as those suffering from severe trauma or critical illness. These studies primarily track metabolic outcomes like nitrogen balance to assess the benefits of the therapy.

Q: Why would a doctor prescribe Аминовен instead of just increasing protein intake?

A: It is prescribed only when oral or enteral (via the digestive tract) nutrition is impossible, insufficient, or contraindicated. This means the patient cannot safely consume or absorb the necessary nutrients from standard protein intake, requiring intravenous delivery to bypass the digestive system.

Q: Can Аминовен interact with common pain relievers or antibiotics?

A: Official labeling states that systemic pharmacological interactions with other medicinal products are not known to be documented. However, the solution must never be mixed with any other medicines in the same container due to a high risk of physical and chemical incompatibility and contamination.

Q: Does Аминовен interact with blood thinners like warfarin?

A: Systemic pharmacological interactions with other medicinal products, including blood thinners, are not known to be documented in the official labeling. However, combining this solution with any other medication in the same infusion container is strictly prohibited due to incompatibility risks.

Q: Is it normal for the infusion site to feel cold or slightly irritated with Аминовен?

A: Local adverse reactions at the infusion site are documented in official safety information. These can include irritation of the vein wall, pain, redness, or swelling (thrombophlebitis), particularly when the infusion is administered via a peripheral vein.

Q: Does Аминовен affect blood pressure or heart rate?

A: Official safety data has reported that tachycardia (fast heart rate) and changes in blood pressure, including both hypotension (low) and hypertension (high), have occurred as rare undesirable effects in combined nutritional product information.

Q: Are there alternatives to Аминовен for people who need nutritional support?

A: Yes, this solution is used as part of nutritional support when normal feeding is impossible. Alternatives include other commercially available amino acid solutions or, whenever possible, other forms of nutritional support like enteral (tube) feeding.

Q: Can Аминовен cause headaches or dizziness?

A: Headaches and dizziness are listed as uncommon undesirable effects that may occur according to combined amino acid and nutritional product safety information. These effects may be monitored by a healthcare professional.

Q: Are there different concentrations of amino acids in the various Аминовен products?

A: Yes, the different products (e.g., 10% versus 15% solutions) contain different total concentrations of amino acids. The concentration used is determined by the patient's individual protein and fluid requirements.

Q: Does Аминовен help with muscle wasting or weakness?

A: The solution's mechanism of action is to provide the structural units for protein synthesis. This is intended to support tissue repair and muscle maintenance, which helps counteract the severe tissue breakdown common during critical illness or recovery.

Q: Why is the infusion rate of Аминовен important?

A: The infusion rate is critical because regulatory guidelines mandate a maximum rate that must not be exceeded. Infusing too quickly can lead to transient systemic effects such as nausea, vomiting, shivering, and carries a risk of severe metabolic complications.

Q: Are there any religious or dietary concerns related to the ingredients of Аминовен?

A: The active ingredients are a blend of purified, synthetic L-amino acids. Official labeling does not list animal-derived components. For patients with specific religious or dietary requirements, it is generally recommended to confirm the full composition with a healthcare provider.

Q: Why do people use Аминовен when they cannot eat normally?

A: It is used to provide the body with essential protein building blocks to maintain a positive nitrogen balance. This is necessary when the patient cannot consume or safely absorb nutrients through the mouth or digestive tract due to illness or trauma.

Q: What are the signs of severe metabolic complications like hyperammonemia?

A: Hyperammonemia (high ammonia levels in the blood) is a possible severe complication if the solution is improperly administered or if the patient has underlying issues. Signs reported in official documentation can include confusion, abnormal breathing, an abnormal heartbeat, pale skin, seizures, sweating, or vomiting. The appearance of these signs is typically monitored closely by the healthcare team.

Advertisements

How should Аминовен be stored and disposed of?

How to Store and Dispose of Аминовен

The storage and disposal of Аминовен (Aminoven) must strictly follow the conditions defined in the official regulatory labeling to ensure product quality.

Storage Conditions

Requirement Condition
Temperature Store at or below 25 C; Do not freeze.
Light Protection Must be protected from light and kept in the outer carton.
Container Integrity Use only if the solution is clear and particle-free and the container is undamaged.
Child Safety Keep out of the reach and sight of children.

Stability and Disposal

The product's shelf-life applies to the unopened container. Once opened, the solution must be used immediately. Any solutions mixed with other components (e.g., TPN admixtures) must be used within specific, short, refrigerated time frames, typically no longer than 24 hours at 2 C to 8 C. Any unused medicinal product or waste material must be discarded according to approved hospital procedures and local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Аминовен found in:

A-Z Index: